Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

Month: November 2020

2 / 3

How have Index Inclusions & Exclusions performed?

How does getting added to or getting removed from the NIFTY affect a stock's performance? Should you buy index inclusions for the passive inflows that will ...
Featured-Image-13.jpeg

Happy Diwali 2020! What We Predicted Last Year, and More For This Year

All of us at Capitalmind wish you a Very Happy and Joyous Diwali 2020. Hope the next year will be filled with joy and wealth, even if it’s not in that ...
Diwali-scaled.jpg

Does Diwali bring cheer to NIFTY? | A look at the odds

Diwali marks the beginning of the Hindu New Year and its widely believed that trading on this day brings wealth and prosperity throughout the ...
featured-image.jpg

The Market Loves Drugs & Tech; Hates Power and the Powerful

The performance of the Nifty 50 index has been patchy from last Samvat because of the outbreak of Covid-19. The lockdown imposed from the last week of March ...
markets-love-hate-sectors-min.jpg

Blockbuster Earnings backed by Strong Demand for Balkrishna Industries

Highlight of Balkrishna's 2nd quarter earnings Strong sales growth of 46% on the back of agricultural tyre ...
Earnings-Report-1.jpg

Capitalmind Premium Slack Community – A tucked-away treasure trove

In this post, I sit back and reflect on what the Capitalmind community is all about and how it has helped me (and many others) get better. Better not just at ...
image-for-slack.jpg

Gland Pharma IPO: Should you invest?

Hyderabad based Gland Pharma will be launching the biggest IPO in Indian Pharma sector on 9th November. It’s one of the fastest growing B2B player in the ...
Gland-pharma-Featured-image-2.jpg

Can you really beat the market? Introducing the Capitalmind Premium League

It's that time of the year. When the COVID-impacted 2020 version of the Dream11 Indian Premier League winds down, and financial media is rife with Diwali picks ...
Premium-League.jpg

A good quarter despite tepid sales growth for Dr Lal PathLabs

Dr Lal Pathlabs, a leading diagnostic company has come up with its Q2 Results. We look at the results and management commentary in this post. ...
Earnings-Report-1.jpg

Is the Nippon CPSE Bond Plus SDL ETF 2024 Worth It?

There's a New Fund Offer (NFO) of a Bond ETF in town. And it's going to do the "safe" thing. The Nippon India CPSE Bond Plus SDL Sep 2024 ETF will: invest ...
Nippon-ETF-scaled.jpg